Literature DB >> 8951903

Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I.

D Huić1, M Medvedec, D Dodig, S Popović, D Ivancević, Z Pavlinovic, M Zuvic.   

Abstract

The aim of this study was to investigate the influence of the diagnostic administration of 74 MBq 131I on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Retention measurements were performed using a whole-body counter in 24 patients 6 weeks after total thyroidectomy. Profile scans were performed 2, 24, 48 and 72 h after the administration of the diagnostic dose and 72 h after the administration of the ablation-therapeutic dose (4.4 GBq). The mean ( +/- S.D.) effective half-life of the diagnostic dose in thyroid remnants was 40.3 +/- 23.0 h. The uptake in the thyroid remnants of the subsequent ablation dose 72 h after administration was 30.4 +/- 19.8% of that predicted from the diagnostic study. The greater reduction in uptake was associated with the longer half-life of iodine and higher uptake in the thyroid remnants at 24 h, with a longer interval between surgery and administration of the diagnostic dose and a shorter period between administration of the diagnostic and ablation doses. Our results show that a diagnostic dose of 74 MBq 131I markedly reduces thyroid uptake of an ablation dose of 131I. This should be taken into account during radiation dose planning whenever a quantitative dosimetric study is to be performed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8951903

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  Seeking a radiobiological explanation for thyroid stunning.

Authors:  M Medvedec
Journal:  Eur J Nucl Med       Date:  2001-03

2.  Decreased uptake after fractionated ablative doses of iodine-131.

Authors:  Hurng-Sheng Wu; Huey-Herng Hseu; Wan-Yu Lin; Shyh-Jen Wang; Yao-Chi Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-04       Impact factor: 9.236

3.  Micrometastasis of papillary thyroid carcinoma in a human immunodeficiency virus-infected patient: a case report and discussion.

Authors:  Célia Lloret Linares; Didier Troisvallets; Pierre Sellier; André Aurengo; Laurence Leenhardt
Journal:  Med Oncol       Date:  2009-08-06       Impact factor: 3.064

4.  The Effect of Diagnostic Absorbed Doses from 131I on Human Thyrocytes in Vitro.

Authors:  Zbigniew Adamczewski; Mariusz Stasiołek; Bolesław Karwowski; Marek Dedecjus; Daria Orszulak-Michalak; Anna Merecz; Przemysław W Śliwka; Bartosz Puła; Andrzej Lewiński
Journal:  Int J Mol Sci       Date:  2015-06-29       Impact factor: 5.923

5.  The Molecular Effect of Diagnostic Absorbed Doses from 131I on Papillary Thyroid Cancer Cells In Vitro.

Authors:  Mariusz Stasiołek; Zbigniew Adamczewski; Przemysław W Śliwka; Bartosz Puła; Bolesław Karwowski; Anna Merecz-Sadowska; Marek Dedecjus; Andrzej Lewiński
Journal:  Molecules       Date:  2017-06-15       Impact factor: 4.411

6.  A Clinical Trial of Optimal Time Interval Between Ablation and Diagnostic Activity When a Pretherapy RAI Scanning Is Performed on Patients With Differentiated Thyroid Carcinoma.

Authors:  Yafu Yin; Qiufen Mao; Song Chen; Na Li; Xuena Li; Yaming Li
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.